Irinotecan and temozolomide for Ewing sarcoma: The memorial sloan-kettering experience

Pediatric Blood and Cancer

Volumn 53, Issue 6, 2009, Pages 1029-1034

  Casey, Denise A ^a   Wexler, Leonard H ^a   Merchant, Melinda S ^a   Chou, Alexander J ^a   Merola, Pamela R ^a   Price, Anita P ^a   Meyers, Paul A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Ewing sarcoma; Irinotecan; Temozolomide

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; IRINOTECAN; LOPERAMIDE; OCTREOTIDE; STEROID; TEMOZOLOMIDE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; BACTEREMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURGERY; CHILD; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG TOLERABILITY; EWING SARCOMA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN TISSUE; INTRAVENOUS ADMINISTRATION; MALE; MEDICAL RECORD REVIEW; METASTASIS; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT CANCER; RETROSPECTIVE STUDY; SCHOOL CHILD; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CHILD; CHILD, PRESCHOOL; COLITIS; DACARBAZINE; DIARRHEA; FEMALE; HUMANS; MALE; NEUTROPENIA; PNEUMONIA; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SARCOMA, EWING'S; THROMBOCYTOPENIA; YOUNG ADULT;

EID: 71049179078     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22206     Document Type: Article

References (44)

1. Esiashvili N, Goodman M, Marcus RB. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades. J Pediatr Hematol Oncol 2008;30:425-430.
2. Ludwig A. Ewing sarcoma: Historical perspectives, current state-of- the-art, and opportunities for targeted therapy in the future. Curr Opin Oncol 2008;20:412-418.
3. Leavey PJ, Mascarenhas L, Marina N, et al. Prognostic factors for patients with Ewing sarcoma at first recurrence following multi-modality therapy: A report from the Children's Oncology Group. Pediatr Blood Cancer 2008;51:334-338.
4. McTiernan AM, Cassoni AM, Driver D, et al. Improving outcomes after relapse in Ewing's Sarcoma: Analysis of 114 patients from a single institution. Sarcoma 2006;2006:1-8.
5. Bacci G, Ferrari S, Longhi A, et al. Therapy and survival after recurrence of Ewing's tumors: The Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol 2003;14:1654-1659.
6. Kolb EA, Kushner BH, Gorlick R, et al. Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. J Clin Oncol 2003;21:3423-3430. (Pubitemid 46594075)
7. Rodriguez-Galindo C, Billups CA, Kun LE, et al. Survival after recurrence of Ewing tumors: The St Jude Children's Research Hospital experience, 1979-1999. Cancer 2002;94:561-569.
8. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Eng J Med 2003;348:694-701.
9. Reardon DA, Quinn JA, Rich JN, et al. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer 2005;104:1478-1486. (Pubitemid 41356163)
10. Jones SF, Gian VG, Greco FA, et al. Phase I. Trial of irinotecan and temozolomide in patients with solid tumors. Oncology (Williston Park) 2003;17:41-45.
11. Gruber ML, Buster WP. Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma. Am J Clin Oncol 2004;27:33-38. (Pubitemid 38176289)
12. Wagner LM, Crews KR, Iacono LC, et al. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res 2004;10:840-848. (Pubitemid 38198882)
13. Kushner BH, Kramer K, Modak S, et al. Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol 2006;24:5271-5276. (Pubitemid 46631373)
14. Thompson PA, Gupta M, Rosner GL, et al. Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: A report from the children's oncology group. Cancer Chemother Pharmacol 2008;62:1027-1037.
15. Houghton JP, Chesire JP, Hallman JD II, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995;36:393-403.
16. Ma MK, Zamboni WC, Radomski KM, et al. Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan. Clin Cancer Res 2000;6:813-819.
17. Furman WL, Stewart CF, Poquette CA, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 1999;17:1815-1824.
18. Newlands ES, Stevens MFG, Wedge SR, et al. Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997;23:35-61.
19. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999;17:2762-2771. (Pubitemid 29415233)
20. Stupp R, Mason WP, ven den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996. (Pubitemid 40349501)
21. Nicholson HS, Kretschmar CS, Krailo M, et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: A report from the children's oncology group. Cancer 2007;110:1542-1550. (Pubitemid 47463069)
22. Reni M, Zaja F, Mason W, et al. Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer 2007;96:864-867. (Pubitemid 46452291)
23. Christodoulou C, Bafaloukos D, Kosmidis P, et al. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 2001;12:249-254. (Pubitemid 32223877)
24. Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: A phase II study. J Clin Oncol 2004;22:2101-2107. (Pubitemid 41095143)
25. Quirt I, Verma S, Petrella T, et al. Temozolomide for the treatment of metastatic melanoma: A systematic review. Oncologist 2007;12:1114-1123. (Pubitemid 350007023)
26. Boyar MS, Hesdorffer M, Keohan ML, et al. Phase II study of temozolomide and thalidomide in patients with unresectable or metastatic leiomyosarcoma. Sarcoma 2008;2008:1-7.
27. Middlemas DS, Stewart CF, Chesire PJ, et al. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin Cancer Res 2000;6:998-1007.
28. Nicholson HS, Krailo M, Ames MM, et al. Phase I study of temozolomide in children and adolescents with recurrent solid tumors: A report from the Children's Cancer Group. J Clin Oncol 1998;16:3037-3043. (Pubitemid 28417424)
29. 6- methylguanine-DNAmethyltransferase andmismatch repair phenotypes in xenograft models. Clin Cancer Res 2000;6:4110-4118.
30. Wagner LM, McAllister N, Goldsby RE, et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 2007;48:132-139. (Pubitemid 44958268)
31. Anderson P, Kopp L, Anderson N, et al. Novel bone cancer drugs: Investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma). Expert Opin Invest Drugs 2008;17:1703-1715.
32. Kushner BH, Meyers PA, Gerald WL, et al. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. J Clin Oncol 1995;13:2796-2804.
33. Womer RB, West DC, Krailo MD, et al. Randomized comparison of every-two-week vs. every-three-week chemotherapy in Ewing sarcoma family of tumors (ESFT). J Clin Oncol 2008 ASCO Annu Meeting Proc 2008;26:10504.
34. Dubois SG, Krailo MD, Lessnick SL, et al. Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: A report form the Children's Oncology Group. Pediatr Blood Cancer 2009;52:324-327.
35. Ferrari S, Brach del Prever A, Palmerini E, et al. Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma. Pediatr Blood Cancer 2009;52:581-584.
36. Whelan JS, McTiernan A, Kakouri E, et al. Carboplatin-based chemotherapy for refractory and recurrent Ewing's tumours. Pediatr Blood Cancer 2004;43:237-242. (Pubitemid 39025305)
37. Van Winkle P, Angiolillo A, Krailo M, et al. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: The Children's Cancer Group (CCG) experience. Pediatr Blood Cancer 2005;44:338-347. (Pubitemid 40316026)
38. Saylors RL III, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A Pediatric Oncology Group phase II study. J Clin Oncol 2001;19:3463-3469. (Pubitemid 32730082)
39. Hunold A, Weddeling N, Paulussen M, et al. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer 2006;47:795-800. (Pubitemid 44476756)
40. Wagner LM, Crews KR, Stewart DF, et al. Reducing irinotecan-associated diarrhea in children. Pediatr Blood Cancer 2008;50:201-207.
41. Saliba F, Hagipantelli R, Misset JL, et al. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: A prospective assessment. J Clin Oncol 1998;16:2745-2751. (Pubitemid 28363040)
42. Sergio GC, Félix GM, Luis JV. Activated charcoal to prevent irinotecan-induced diarrhea in children. Pediatr Blood Cancer 2008;51:49-52.
43. Furman WL, Crews KR, Billups C, et al. Cefixime allows greater dose escalation of oral irinotecan: A phase I study in pediatric patients with refractory solid tumors. J Clin Oncol 2006;24:563-570. (Pubitemid 46630418)
44. Wagner LM, Villablanca JG, Stewart CF, et al. Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: A new approach to neuroblastoma therapy consortium study. J Clin Oncol 2009;27:1290-1294.